Background Ghrelin has a protective effect on endothelial cells. Endothelial cell dysfunction is associated with cardiovascular disease (CVD) and CVD remains the leading cause of morbidity in hemodialysis (HD) patients. Acylated ghrelin (A-Ghr) is the functional form of ghrelin, so we hypothesized that A-Ghr is associated with the occurrence of CVD in HD patients. Methods We conducted a prospective cohort study in 412 HD patients. The cohort was sub-grouped into low and high A-Ghr groups according to the median A-Ghr level of 4.88 pg/mL. The association between the low/high A-Ghr groups and the incidence of CVD were analyzed. Results The HD patients in a low A-Ghr group had a greater risk of incidental CVD than those in a high A-Ghr ghrelin. This association remained significant after the adjustment for possible confounding factors, including age, gender, HD duration, BMI, diabetes, albumin, nPCR and Charlson's comorbidity index score. Conclusion It appears that a low serum A-Ghr level is associated with the development of CVD in HD patients.
Introduction
Ghrelin is a 28-amino acid peptide initially identified from rat stomach (1) . In humans, it is mainly secreted from the stomach, and acts as the endogenous ligand for the growth hormone secretagogue receptor (GHS-R) (2, 3) . There are two subtypes of GHS-R, GHS-R subtype 1a (GHS-R1a) and subtype 1b. GHS-R1a is the functionally active and signal transducing form (4, 5) . GHS-R1a is expressed in many tissues, such as pituitary, thyroid gland, pancreas and cardiovascular tissue, including myocardial and endothelial cell (3, 6, 7) . Ghrelin has two major endogenous forms, acylated ghrelin (A-Ghr) and unacylated ghrelin (UAGhr). A-Ghr can bind GHS-R1a and exert biological function, but this is not true of the unacylated form (8) . Many physiological actions are associated with ghrelin, including the regulation of growth hormone (GH), the increase of appetite and the involvement in carbohydrate metabolism (3) .
The effects of ghrelin on cardiovascular disease (CVD) have been noted recently. Some studies revealed that the administration of ghrelin improved cardiac function in rats, healthy humans, and cachectic patients with congestive heart failure (9-11). The beneficial effect of ghrelin might come from the endothelial cell protection in the patient. Recent studies have suggested protective effects of ghrelin on human endothelial cells, such as inhibiting cytokine-related pro-inflammatory processes and angiotensin II-induced migration of endothelial cells (12, 13) . Clinical studies further indicated that the blood ghrelin levels are inversely related to the carotid intima-media thickness in patients with carotid atherosclerosis (14, 15) . It is reasonable to presume that endogenous ghrelin plays important roles in protecting the endothelial cells from inflammatory processes and in preventing the development of atherosclerosis. It seems that people with lower blood levels of ghrelin have a higher risk of CVD.
CVD remains the leading and more frequent cause of morbidity and mortality in patients with chronic HD compared with general population. In contrast, people with renal failure have higher levels of total ghrelin than healthy controls (16, 17) . With this paradoxical observation, it is interesting to ask whether A-Ghr, the functionally active form, is more closely correlated with CVD than total ghrelin in HD patients. We hypothesized that the A-Ghr level, rather than the total ghrelin level, might be associated with the occurrence of CVD in HD patients. To date, there has been no study focusing on the relationship between serum ghrelin levels and the occurrence of clinical evident CVD in HD patients. To answer the question, we conducted a prospective cohort study in prevalent HD patients with low and high serum A-Ghr, and observed the occurrence of CVD in these two groups of patients.
Materials and Methods

Cohorts
The prospective cohort study was conducted in a HD center of a university-affiliatted teaching hospital in northern Taiwan. A total of 412 consecutive and non-selective prevalent HD patients were enrolled in this dynamic cohort. All of the participants received regular HD at least twice per week for three months or more and they were included in this cohort between November 1, 2005 and October 31, 2006. We observed the cohort until October 31, 2008. All participants signed a consensus form on entering the cohort.
Data collection & measurements
At baseline, the basic information and a blood sample were collected. Demographic data (age and gender), anthropocentric characteristics (body height, weight after dialysis, calculated body mass index (BMI), and waistline), duration of HD, smoking status (current and past smoker), and clinical information (status of diagnosed diabetes mellitus and hypertension, and the hospitalization and causes of CVD during the study period) were collected from medical records and questionnaires. Diagnosed diabetes was defined as any patient who has two fasting plasma glucose levels of 126 mg/dL or is using the hypoglycemic agents. Diagnosis of hypertension was made if the patient's systolic blood pressure is consistently 140 mmHg or greater, diastolic blood pressure is consistently 90 mmHg or greater, or the patient was receiving antihypertensive medication. Duration of HD was identified as the time that patient had received regular HD before his enrollment in our study. Patients' Kt/ V [both by Gotch (G) and Daugirdas (D)], urea reduction ratio (URR), normalized protein catabolic rate (nPCR), serum albumin, total cholesterol, triglyceride, and glucose levels were obtained at baseline. We used Charlson's index score as the comorbidity measurement (18) , and the data were collected from medical records and questionnaires. We recorded and calculated the data of malignant solid tumor, liver disease, diabetes, peptic ulcer, malignant lymphoma, leukemia, dementia, connective tissue disease, chronic pulmonary disease, acquired immune deficiency syndrome, peripheral vascular disease, myocardial infarction, hemiplegia, congestive heart failure and cerebrovascular disease as Charlson's criteria.
The observed endpoint was defined as the admission to hospital during the study period due to CVD. We included acute coronary syndrome (ACS), peripheral arterial occlusive disease (PAOD), and cerebral infarct as CVD. Evidence for ischemia or arterial occlusion in electrocardiogram, sonogram or radiology study is necessary for the diagnosis for each episode of CVD. The diagnosis of CVD was made by cardiologist or neurologists during the hospitalization of these patients. We collected 71 CVD events; these were hospitalized for 36 ACS, 19 PAOD and 16 stroke. The followup period was identified from the time that patient was enrolled up to the end of October 2008, or the date of endpoint. For patients who received a kidney transplant, the follow-up was censored at the time of transplantation.
Specimens
Blood samples were collected just before the beginning of HD after 8 hours fasting, and immediately transferred to chilled polypropylene tubes (SST Gel and Clot Activator, Becton Dickinson VACUTAINER Systems, Rutherford, NJ 07070), centrifuged at room temperature, and frozen within 1 hour of collection and stored at -70 until the ghrelin enzyme-linked immunoabsorbant assays (ELISA) were performed with standardized kits.
Screening for ghrelin levels was performed by one technician in a single laboratory in one batch. The A-Ghr and UAGhr levels were measured using the commercially available ELISA kits, Human Acylated Ghrelin ELISA Kit (Catalog # A05106, SPI-BIO, Bertin, France) and Human Unacylated Ghrelin ELISA Kit (Catalog # A05119, SPI-BIO, Bertin, France), respectively. The operations were in accord with the manufacturer's protocol. Total ghrelin level was the sum of measured A-Ghr and UA-Ghr levels. The intra-assay and inter-assay coefficients of variation were 4.4% and 4.5% of UA-Ghr, and 6.2% and 6.7% of A-Ghr, separately.
Grouping and statistical analysis
We divided the participants into the low and high A-Ghr groups. The cut point was the median, 4.88 pg/mL, of measured A-Ghr level. Demographics and cardiovascular risk factors were expressed by frequency (percentage) and compared by chi-square test or Fisher exact test in categorical variables. The hazard function of incident CVD event was modeled as a time-to-event outcome using the Cox proportional hazards model. Predictors in these models included patient demographics and clinical measures. Hazard ratios (HR) and associated 95 percent confidence intervals (95% CI) were calculated to estimate the risk of incident CVD event compared with non-CVD event among the low aclyated group versus the high aclyated ghrelin group. For minimization of the effect of potential confounders, we developed models that adjusted for various variables, including age (!60 vs <60 years), gender (male vs female), BMI (!24 vs <24), waistline (!80 cm in females, !90 cm in males), hypertension, diabetes, serum albumin (<3.5 vs !3.5 g/dL), serum total cholesterol (!200 vs <200 mg/ dL), serum triglyceride (!150 vs <150 mg/dL), URR (< 0.65 vs !0.65), Kt/V (both Gotch and Daugirdas, <1.2 vs !1.2), nPCR (<0.8 vs !0.8 g/kg/day), HD duration (!3 vs <3 years), smoking status (current smoker and past smoker), and Charlson's comorbidity index score (!5 vs < 5). Two-tailed p value of less than 0.05 was considered significant. All analyses used procedures of the SAS for Windows, version 9.1 (SAS Institute, Cary, NC).
T a b l e 1 . B a s i c Ch a r a c t e r i s t i c s o f t h e 4 1 2 S t u d i e d S u b j e c t s
Results
In this study, 412 HD patients (60.7±14.0 years, 169 males and 243 females) were enrolled. Basic characteristics are shown in Table 1 . The total follow-up period was 11053.8 patient-months, and the average personal follow-up period was 26.8±11.4 months. There were 71 CVD events (37 males and 34 females) included.
Comparison of characteristics of the study subjects between the low and high A-Ghr groups are shown in Table 2 . All characteristics, but nPCR and HD duration, were not significant different between these two groups ( Table 2 ). The lower nPCR and shorter HD duration were associated with lower A-Ghr level.
We analyzed the possible risk factors of CVD events in these patients by Cox proportional hazards model. In univariate analysis, older age (!60 years, HR 1. Table 3 .
Age, gender, HD duration, BMI, diabetes, albumin level, nPCR level, Charlson's comorbidity index score, and both A-Ghr and total ghrelin levels might be mutual confounding variables, which are difficult to disentangle. To elucidate the individual impact factor on the CVD-events hazard ratios, the various significant variables were further examined by T a b l e 2 . Co mp a r i s o n b e t we e n S u b j e c t s wi t h L o we r a n 
l i n L e v e l s S t r a t i f i e d b y Me d i a n
Discussion
Our study has demonstrated that the long-term HD patients in the low A-Ghr group have greater risk of incidental CVD, but not in the low total ghrelin group. This association remains significant after adjustment of the possible confounding factors, including age, gender, HD duration, BMI, diabetes, albumin, nPCR and Charlson's comorbidity index score.
The endothelial cells form a physical barrier between the lumen and the vessel wall and play important roles in vascular homeostasis and pathogenesis of CVD. Physically the initial damage of the endothelium can be reversed by various repairing mechanism, such as eliciting production of endothelium-derived nitric oxide (NO), to restore endothelial integrity (19, 20) . Abnormal endothelial function accelerates endothelial damage, thrombosis, vasoconstriction, and rapid growth of atherosclerotic plaques (21, 22) . It is rational to speculate that factors which promote the process of endothelial repair decrease the occurrence of CVD.
It has been documented that ghrelin plays a role in reducing damage and maintaining the integrity of endothelial cells. Ghrelin and GHSR exist in vascular tissue (3, 12) . Li et al found that ghrelin inhibits pro-inflammatory cytokine production and endotoxin-induced cytokine production in human endothelial cells in vitro (12) . Rossi et al reported that ghrelin inhibits the angiotensin II-induced migration of human endothelial cells (23) . Ghrelin can also inhibit homocysteine-induced endothelial dysfunction in human endothelial cells (24) . Endothelial damage seems to induce in- crement of ghrelin activity. Significantly up-regulated GHSR density has been found in atherosclerotic coronary arteries in rats (25) . It is reasonable to say that ghrelin plays some role in the process of endothelial repair. In addition to direct endothelial repair, ghrelin also indirectly participates in the endothelial repair via the neuroendocrine route. Ghrelin acts as the endogenous ligand for the GHSR, which is the third pathway regulating GH release other than growth-hormone-releasing hormone and somatostatin (26, 27) . Intravenous ghrelin administration in healthy humans can stimulate GH release (28) . It has been noted that GH supplementation increases circulating endothelial progenitor cell (EPC) levels and NO bioavailability in healthy volunteers (29) . The increase of circulating EPC might play an important role in endothelial repair (20) . These changes may be beneficial in CVD, and ghrelin may reinforce these protective effects via the release of GH.
T a b l e 3 . Un i v a r i a t e Ha z a r d Ra t i o f r o m Co x P r o p o r t i o n Ha z a r d Mo d e l f o r Ca r d i o v a s c u l a r Di s e a s e E v e n t s
The findings in literature are conflicting about the relationship of insulin resistance (IR) and ghrelin. Some information from the laboratory data and clinical trials hints at the complexity of the relationship between ghrelin and IR (30-37). For instance, even in children, A-Ghr is related positively with the homeostasis model assessment of IR (HOMA-IR) in the Pacifico et al article (38) , and negatively with HOMA-IR in the Celi et al article (39) . Kiewiet et al have reported that ghrelin injection has a strong improvement in insulin sensitivity (40) . Moreover, ghrelin production is downregulated by IR and hyperinsulinemia (41, 42) . IR could increase EPC apoptosis, and decrease EPC migration, glucose transporter 4 translocation, and NO production in endothelial cells mediated by inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt intracellular signaling pathway of insulin receptor (28) . Administration of ghrelin inhibits high glucose-induced endothelial apoptosis in vitro and improves endothelial function in vivo by increasing NO bioactivity via the PI3K/Akt pathway (43, 44) .
The protective effect of endothelial cells by ghrelin may be more important in chronic kidney disease (CKD) patients. It has been known that ghrelin concentrations in uremic patients are higher than that in healthy controls (16, 17) . This is caused by impaired clearance and/or metabolism of ghrelin in the kidney (45, 46) . Paradoxically, the high total ghrelin levels seem not to protect uremic patients from more CVD events. It is likely that the amount of elevated ghrelin is still relatively insufficient because of overwhelming endothelial damage in these patients.
T a b l e 4 . Mu l t i v a r i a t e Ha z a r d Ra t i o f r o m Co x P r o p o r t i o n Ha z a r d Mo d e l f o r Ca r d i o v a s c u l a r Di s e a s e E v e n t s
It has been considered that ghrelin becomes active only in its acylated form when the third serine residue is esterified by octanoic acid (1). Indeed, Kieweit et al have found that only the simultaneous injection of A-Ghr and UA-Ghr can increase the insulin sensitivity (40) . It seems that the acylated form is imperative for physiologic effects of ghrelin, and UA-Ghr plays some additional or assistant roles, at least in some reaction, with coexisted A-Ghr. A sufficient AGhr level may be important in carrying out its physiologic effects.
In uremic patients most of increased ghrelin comes from UA-Ghr other than A-Ghr (46) . The specific ghrelin profile in uremic patients might explain why only the relatively higher A-Ghr, not total ghrelin, in uremic patients is protective for CVD events in our study (Table 4) . It implies that an insufficient A-Ghr level, even coexistant with sufficient UA-Ghr, may not provide the sufficient physiologic effects. We believe that the serum A-Ghr level rather than the total ghrelin level has more important pathophysiological roles in uremic patients.
It is interesting in our study lower BMI or lower HD duration had higher CVD in HD patients. In fact, it has been found by Wu et al that high BMI is not associated with severe CVD in CKD patients in Taiwan (47) . The present HD patients have a similar condition. It may be due to some characteristics of CKD and uremia patients in Taiwan, probably as more severe cachexia or malnutrition and relatively late renal replacement therapy (48) , coexisting with CVD and/or predisposing the occurrence of CVD. As a similar reason, the early onset of CVD after the beginning of dialysis may represent this condition. It is an attractive problem worth of further study.
Several limitations should be mentioned. First, we have no some indices of nutrition and inflammation, such as creatinine, high sensitive C-reactive protein, blood urea nitrogen or white blood cell count. However, we included nPCR and albumin in our study. Albumin reflects nutrition and some inflammation status, and nPCR is one marker for nutrition. Albumin is no significant difference in baseline, and these two variables have been included in the multivariate model. Second, our A-Ghr and UA-Ghr levels were assessed in one batch by one technician, but other lab data including lipid profiles and glucose level not. However, these assessments were following the standard processes, and only used for diagnosis. Third, in our analysis gender was not significant in the crude model, however age and gender was still included in multivariate model to adjust for potential confounding. If gender was excluded, the CVD risk still exists in A-Ghr (OR (95%CI), p value: 1.29 (1.04-1.61), 0.0215 in model I and 1.29 (1.04-1.60), 0.0235 in model II). It is more conservative to avoid the radical finding. Finally, we followed the HD patients, and reported a protective effect to CVD in elevated A-Ghr. Although our observation does not tell whether an insufficient A-Ghr level predisposes patients to CVD onset, or a low A-Ghr is simply a surrogate marker of their clinical condition. The mechanism needs further study.
In summary, we found that HD patients with a lower serum A-Ghr level have a greater risk of developing CVD. The serum A-Ghr level might be a predictor for the development of incidental CVD events in HD patients.
